Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Liu, Ling ^a   Aboud, Orwa ^a   Jones, Richard A ^a   Mrak, Robert E ^d   Griffin, W Sue T ^a,b,c   Barger, Steven W ^a,b,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^d MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Alzheimer's disease (ad); Amyloid beta (a ); Apolipoprotein e (apoe); Beta amyloid precursor protein ( app); Excitotoxicity; Glutamate; Interleukin 1 (il 1 ); Neuroinflammation; Neuronal stress; Secreted amyloid precursor protein (sapp)

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APOLIPOPROTEIN E; GLUTAMIC ACID; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL ACTIVATION; CONTROLLED STUDY; DRUG PELLET; ENZYME INHIBITION; FETUS; GENE EXPRESSION; GLIA CELL; IMMUNOFLUORESCENCE TEST; MALE; NERVE CELL CULTURE; NERVE CELL EXCITABILITY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; BLOTTING, WESTERN; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GLUTAMIC ACID; INFLAMMATION; INTERLEUKIN-1BETA; MALE; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 83455213559     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-175     Document Type: Article

References (72)

1. Blackman JA, Worley G, Strittmatter WJ. Apolipoprotein E and brain injury: implications for children. Dev Med Child Neurol 2005, 47:64-70.
2. D'Arcangelo G. Apoer2: a reelin receptor to remember. Neuron 2005, 47:471-473. 10.1016/j.neuron.2005.08.001, 16102527.
3. D'Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T. Reelin is a ligand for lipoprotein receptors. Neuron 1999, 24:471-479. 10.1016/S0896-6273(00)80860-0, 10571240.
4. Strittmatter WJ, Bova Hill C. Molecular biology of apolipoprotein E. Curr Opin Lipidol 2002, 13:119-123. 10.1097/00041433-200204000-00002, 11891413.
5. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:11183-11186. 10.1073/pnas.91.23.11183, 45191, 7972031.
6. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009,
7. Boschert U, Merlo-Pich E, Higgins G, Roses AD, Catsicas S. Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol Dis 1999, 6:508-514. 10.1006/nbdi.1999.0251, 10600406.
8. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci 2006, 26:4985-4994. 10.1523/JNEUROSCI.5476-05.2006, 16687490.
9. Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmuller F, Muller U, Kurz A, Zimmer R, Evans RM, et al. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 2000, 55:480-483.
10. Grimaldi LM, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, Biunno I, De Bellis G, Sorbi S, Mariani C, et al. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol 2000, 47:361-365. 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N, 10716256.
11. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000, 47:365-368. 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.0.CO;2-G, 10716257.
12. Rebeck GW. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease. Neurosci Lett 2000, 293:75-77. 10.1016/S0304-3940(00)01487-7, 11065142.
13. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008, 9:768-778. 10.1038/nrn2494, 18802446.
14. Griffin WS, Sheng JG, Gentleman SM, Graham DI, Mrak RE, Roberts GW. Microglial interleukin-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. Neurosci Lett 1994, 176:133-136. 10.1016/0304-3940(94)90066-3, 7830934.
15. Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak DR, Nelson SJ, Griffin WS. Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease. J Neuropathol Exp Neurol 1994, 53:231-238. 10.1097/00005072-199405000-00003, 8176406.
16. Sheng JG, Boop FA, Mrak RE, Griffin WS. Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. J Neurochem 1994, 63:1872-1879.
17. Griffin WS, Yeralan O, Sheng JG, Boop FA, Mrak RE, Rovnaghi CR, Burnett BA, Feoktistova A, Van Eldik LJ. Overexpression of the neurotrophic cytokine S100 beta in human temporal lobe epilepsy. J Neurochem 1995, 65:228-233.
18. Mackenzie IR, Miller LA. Senile plaques in temporal lobe epilepsy. Acta Neuropathol (Berl) 1994, 87:504-510.
19. Vezzani A, Balosso S, Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun 2008, 22:797-803. 10.1016/j.bbi.2008.03.009, 18495419.
20. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989, 86:7611-7615. 10.1073/pnas.86.19.7611, 298116, 2529544.
21. Sheng JG, Mrak RE, Griffin WS. Enlarged and phagocytic, but not primed, interleukin-1 alpha-immunoreactive microglia increase with age in normal human brain. Acta Neuropathol (Berl) 1998, 95:229-234.
22. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004, 3:169-176. 10.1111/j.1474-9728.2004.00101.x, 15268750.
23. Gee JR, Ding Q, Keller JN. Age-related alterations of Apolipoprotein E and interleukin-1beta in the aging brain. Biogerontology 2006, 7:69-79. 10.1007/s10522-005-6039-9, 16802110.
24. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998, 65:29-33. 10.1136/jnnp.65.1.29, 2170157, 9667557.
25. Graham DI, Gentleman SM, Nicoll JA, Royston MC, McKenzie JE, Roberts GW, Griffin WS. Altered beta-APP metabolism after head injury and its relationship to the aetiology of Alzheimer's disease. Acta Neurochir Suppl 1996, 66:96-102.
26. Gouras GK, Relkin NR, Sweeney D, Munoz DG, Mackenzie IR, Gandy S. Increased apolipoprotein E epsilon 4 in epilepsy with senile plaques. Ann Neurol 1997, 41:402-404. 10.1002/ana.410410317, 9066363.
27. Teasdale GM, Murray GD, Nicoll JA. The association between APOE epsilon4, age and outcome after head injury: a prospective cohort study. Brain 2005, 128:2556-2561. 10.1093/brain/awh595, 16033781.
28. Corder EH, Robertson K, Lannfelt L, Bogdanovic N, Eggertsen G, Wilkins J, Hall C. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med 1998, 4:1182-1184. 10.1038/2677, 9771753.
29. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 1998, 43:380-383. 10.1002/ana.410430316, 9506555.
30. Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 1996, 17:761-766. 10.1016/0197-4580(96)00104-2, 8892349.
31. Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997, 388:878-881. 10.1038/42257, 9278049.
32. Sheng JG, Mrak RE, Griffin WS. Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. Neuropathol Appl Neurobiol 1996, 22:334-341. 10.1111/j.1365-2990.1996.tb01112.x, 8875468.
33. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999, 96:15233-15238. 10.1073/pnas.96.26.15233, 24803, 10611368.
34. Griffin WS, Liu L, Li Y, Mrak RE, Barger SW. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation 2006, 3:5. 10.1186/1742-2094-3-5, 1435743, 16542445.
35. Barger SW, DeWall KM, Liu L, Mrak RE, Griffin WS. Relationships between expression of apolipoprotein E and beta-amyloid precursor protein are altered in proximity to Alzheimer beta-amyloid plaques: potential explanations from cell culture studies. J Neuropathol Exp Neurol 2008, 67:773-783. 10.1097/NEN.0b013e318180ec47, 18648325.
36. Senechal Y, Kelly PH, Dev KK. Amyloid precursor protein knockout mice show age-dependent deficits in passive avoidance learning. Behav Brain Res 2008, 186:126-132. 10.1016/j.bbr.2007.08.003, 17884188.
37. Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, O'Dowd G, Bowery BJ, Boyce S, Trumbauer ME, Chen HY, et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 1999, 90:1-13. 10.1016/S0306-4522(98)00410-2, 10188929.
38. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997, 77:1081-1132.
39. Laskowitz DT, Matthew WD, Bennett ER, Schmechel D, Herbstreith MH, Goel S, McMillian MK. Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production. Neuroreport 1998, 9:615-618. 10.1097/00001756-199803090-00010, 9559926.
40. Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 2001, 114:107-113. 10.1016/S0165-5728(00)00459-8, 11240021.
41. Koistinaho M, Kettunen MI, Holtzman DM, Kauppinen RA, Higgins LS, Koistinaho J. Expression of human apolipoprotein E downregulates amyloid precursor protein-induced ischemic susceptibility. Stroke 2002, 33:1905-1910. 10.1161/01.STR.0000020124.61998.BC, 12105373.
42. Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE, Griffin WS. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 2000, 20:149-155.
43. Li Y, Wang J, Sheng JG, Liu L, Barger SW, Jones RA, Van Eldik LJ, Mrak RE, Griffin WS. S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J Neurochem 1998, 71:1421-1428.
44. Wu SZ, Bodles AM, Porter MM, Griffin WS, Basile AS, Barger SW. Induction of serine racemase expression and D-serine release from microglia by amyloid beta-peptide. J Neuroinflammation 2004, 1:2. 10.1186/1742-2094-1-2, 483052, 15285800.
45. Li Y, Liu L, Barger SW, Mrak RE, Griffin WS. Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res 2001, 66:163-170. 10.1002/jnr.1208, 11592111.
46. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992, 89:10075-10078. 10.1073/pnas.89.21.10075, 50280, 1359534.
47. Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, Griffin WS. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem Int 2001, 39:341-348. 10.1016/S0197-0186(01)00041-9, 11578769.
48. Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998, 8:65-72.
49. Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol Exp Neurol 1996, 55:273-279. 10.1097/00005072-199603000-00002, 8786385.
50. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25-35]. J Neuroimmunol 1999, 93:45-52. 10.1016/S0165-5728(98)00188-X, 10378868.
51. Barger SW, Mattson MP. Isoform-specific modulation by apolipoprotein E of the activities of secreted beta-amyloid precursor protein. J Neurochem 1997, 69:60-67.
52. Wu S, Basile AS, Barger SW. Induction of serine racemase expression and D-serine release from microglia by secreted amyloid precursor protein (sAPP). Curr Alzheimer Res 2007, 4:243-251.
53. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:9649-9653. 10.1073/pnas.90.20.9649, 47627, 8415756.
54. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994, 145:1030-1035. 1887417, 7977635.
55. Horsburgh K, Fitzpatrick M, Nilsen M, Nicoll JA. Marked alterations in the cellular localisation and levels of apolipoprotein E following acute subdural haematoma in rat. Brain Res 1997, 763:103-110. 10.1016/S0006-8993(97)00411-3, 9272834.
56. Kay A, Petzold A, Kerr M, Keir G, Thompson E, Nicoll J. Temporal alterations in cerebrospinal fluid amyloid beta-protein and apolipoprotein E after subarachnoid hemorrhage. Stroke 2003, 34:e240-243. 10.1161/01.STR.0000100157.88508.2F, 14605321.
57. Lambert JC, Perez-Tur J, Dupire MJ, Galasko D, Mann D, Amouyel P, Hardy J, Delacourte A, Chartier-Harlin MC. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet 1997, 6:2151-2154. 10.1093/hmg/6.12.2151, 9328480.
58. Hesse C, Larsson H, Fredman P, Minthon L, Andreasen N, Davidsson P, Blennow K. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res 2000, 25:511-517. 10.1023/A:1007516210548, 10823584.
59. Fukumoto H, Ingelsson M, Garevik N, Wahlund LO, Nukina N, Yaguchi Y, Shibata M, Hyman BT, Rebeck GW, Irizarry MC. APOE epsilon 3/epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp Neurol 2003, 183:249-253. 10.1016/S0014-4886(03)00088-8, 12957508.
60. Bray NJ, Jehu L, Moskvina V, Buxbaum JD, Dracheva S, Haroutunian V, Williams J, Buckland PR, Owen MJ, O'Donovan MC. Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes. Hum Mol Genet 2004, 13:2885-2892. 10.1093/hmg/ddh299, 15385439.
61. Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A. The apolipoprotein E varepsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging 2009,
62. Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, Ramassamy C, Davignon J, Poirier J. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res 1999, 843:87-94. 10.1016/S0006-8993(99)01894-6, 10528114.
63. Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res 1995, 33:174-178.
64. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303. 10.1016/j.neuron.2009.06.026, 3044446, 19679070.
65. Guo L, LaDu MJ, Van Eldik LJ. A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci 2004, 23:205-212. 10.1385/JMN:23:3:205, 15181248.
66. Colton CA, Brown CM, Cook D, Needham LK, Xu Q, Czapiga M, Saunders AM, Schmechel DE, Rasheed K, Vitek MP. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging 2002, 23:777-785. 10.1016/S0197-4580(02)00016-7, 12392781.
67. Ezra Y, Oron L, Moskovich L, Roses AD, Beni SM, Shohami E, Michaelson DM. Apolipoprotein E4 decreases whereas apolipoprotein E3 increases the level of secreted amyloid precursor protein after closed head injury. Neuroscience 2003, 121:315-325. 10.1016/S0306-4522(03)00436-6, 14521991.
68. Hoe HS, Harris DC, Rebeck GW. Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem 2005, 93:145-155. 10.1111/j.1471-4159.2004.03007.x, 15773914.
69. Ohkubo N, Mitsuda N, Tamatani M, Yamaguchi A, Lee YD, Ogihara T, Vitek MP, Tohyama M. Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway. J Biol Chem 2001, 276:3046-3053. 10.1074/jbc.M005070200, 11042199.
70. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002, 5:405-414.
71. Soriano FX, Martel MA, Papadia S, Vaslin A, Baxter P, Rickman C, Forder J, Tymianski M, Duncan R, Aarts M, et al. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci 2008, 28:10696-10710. 10.1523/JNEUROSCI.1207-08.2008, 2602846, 18923045.
72. Xu J, Kurup P, Zhang Y, Goebel-Goody SM, Wu PH, Hawasli AH, Baum ML, Bibb JA, Lombroso PJ. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci 2009, 29:9330-9343. 10.1523/JNEUROSCI.2212-09.2009, 2737362, 19625523.